NICE to review guidance on Servier's Protelos after legal challenge
This article was originally published in Scrip
Executive Summary
The health technology appraisal body for England and Wales, NICE, will have to review its guidance on Servier's Protelos (strontium ranelate) for preventing osteoporotic fragility fractures, said a UK judge last week. Moreover, NICE must be clear in its reasoning when it reaches a different conclusion from that of "eminent bodies" such as the European Medicines Agency (EMA), according to the judgement.